Burkholderia gladioli has only recently been reported to be a human pathogen. Four cases of B. gladioli infection (including bacteremia, pneumonia, and cervical adenitis) in two adults and two young children are reported. Three of these four patients were severely immunocompromised. Commercial systems were frequently unable to identify this bacterium correctly. Antimicrobial susceptibility patterns indicated that B. gladioli strains were susceptible to the quinolones, aminoglycosides, and imipenem. In vitro laboratory investigations demonstrated that B. gladioli strains were susceptible to complement-mediated lysis of pooled human serum, thus implying that healthy individuals should be immune to infection. These four cases together with three previously reported cases suggest that B. gladioli primarily causes disease in severely immunocompromised individuals. The lack of mortality associated with infection, coupled with susceptibility to serum and lack of recognizable virulence-associated factors, suggests that this species has a low pathogenic potential.
In 1992, Yabuuchi and co-workers [1] proposed a new genus Both of these pneumonic infections occurred in persons with chronic granulomatous disease; one of these infections was named Burkholderia to include members of the ''pseudomallei group'' (rRNA homology group II, not true pseudomonads).
also accompanied by bacteremia. One year later, Khan et al.
[7] described a case of B. gladioli septicemia and empyema The genus was named in honor of W. H. Burkholder, the discoverer of the causative agent of rotten onions. With this proin a 22-year-old man with cystic fibrosis who had recently undergone lung transplantation because of decreasing pulmoposal, seven Pseudomonas-like taxa were transferred to the new genus, including four species known to be human pathogens nary function.
In this report, we describe the expanding spectrum of disease (Burkholderia cepacia, Burkholderia pseudomallei, Burkholderia mallei, and Burkholderia pickettii) . The remaining three associated with four B. gladioli infections (three of which occurred in severely immunocompromised individuals) and sugBurkholderia species (Burkholderia caryophylli, Burkholderia gladioli, and Burkholderia solanacearum) are primarily plant gest that infections due to this unusual pathogen may be underestimated because of the lack of appropriate identification in pathogens and were not associated with human disease at that time. Recently, a proposal to subdivide this group further by the laboratory. transferring B. pickettii and B. solanacearum to a new genus, Ralstonia, has been made on the basis of genetic differences Case Reports between these species and true members of the genus Burkholderia [2] .
Case 1

The phytopathogen B. gladioli (Bacillus marginata, Pseu-
A 55-year-old woman with AIDS was seen at a local hospital domonas marginata) has been most commonly associated with because of a 12-day history of fever, chills, and a pulmonary diseases of the gladiolus plant and decaying onions [3] . In the infiltrate unresponsive to penicillin treatment. She had multiple clinical laboratory, B. gladioli has been isolated rarely from underlying systemic abnormalities (not specified), including the sputum of patients with cystic fibrosis; these isolations were intravenous drug dependency. An infectious disease consult thought to represent transient colonization of the respiratory indicated sepsis, and the diagnosis of subacute bacterial endotract [4, 5] . The first two cases of human infection due to carditis or osteomyelitis was ruled out. A blood specimen was B. gladioli were reported by Ross and colleagues [6] gladitures were collected; these specimens were yellow-green in appearance and occasionally blood-tinged. Cultures yielded oli strains were also evaluated for potential virulence-associated factors -including cell surface hydrophobicity (salt ag-B. gladioli, Staphylococcus aureus, and moderate oronasal flora (not specified). Triple-drug therapy with tobramycin, gregation test, hydrophobic interaction chromatography, and phase partitioning), siderophore production, adherence to HEpticarcillin, and nafcillin was administered for 12 days, and he responded favorably.
2 cells, susceptibility to complement-mediated lysis, and plasmid carriage -by previously reported techniques [9 -11] . Susceptibility to complement-mediated lysis was determined by
Case 3 mixing log-phase bacteria with thawed aliquots of fresh, pooled human serum that had been previously frozen at 070ЊC. Con-A 9-month-old immunosuppressed girl with liver failure who trols included Salmonella typhimurium TV 119 (Ra mutant), had previously undergone an unsuccessful liver transplantation Escherichia coli O111:B4 J5 (Rc mutant), and complementreceived a second liver transplant. She was having moderate inactivated serum (heated to 56ЊC for 30 minutes). acute cellular rejection with fluctuating results of liver function tests when she developed fever of unknown origin; a single blood culture yielded pure growth of B. gladioli. Further fol-
Antimicrobial Susceptibility Studies
low-up data for this patient were not available.
Antimicrobial susceptibility profiles were generated for each strain on MicroScan Dried Overnight (conventional) Suscepti-
Case 4
bility Panels (Dade MicroScan) following the manufacturer's recommendations. A 2-year-old girl was seen at a regional hospital because of a chief complaint of cervical adenitis. Pertinent medical history included recent travel to India. A possible diagnosis of meliResults oidosis (which is due to B. pseudomallei) was entertained, and the patient underwent a lymph node biopsy. Culture of a lymph B. gladioli is an aerobic, motile, nonfermenting, gramnode from the right lower neck region yielded pure growth of negative rod. All strains tested grew on MacConkey agar and B. gladioli.
on basal media at 25ЊC and 35ЊC but not at 42ЊC. All B. gladioli strains were indole-negative, failed to reduce nitrate to nitrite, and were lysine decarboxylase -negative, ornithine decarboxylMethods ase -negative, and arginine dihydrolase -negative. were not hydrolyzed. In only two tests was moderate to strong enzymatic activity (leucine arylamidase and acid phosphatase) or an unidentified gram-negative rod (case 4). Two additional strains previously described by Ross et al. [6] were included detected.
All strains elaborated a siderophore on Chrome Azurol S in this study for comparative purposes. B. gladioli strains were initially characterized by using a standard set of phenotypic agar; all strains were susceptible to complement-mediated lysis, exhibiting a 1.8 to ú6.0 log 10 decrease in cfu within the tests [8] Cellular fatty acid profiles analyzed by the MIDI Microbial 2, had an unusual antimicrobial susceptibility profile compared with the other five strains in that it showed unusual susceptibilIdentification System were consistent with those described for the genus Burkholderia [8] . These profiles contained two cycloity to all agents with the exception of first-generation cephalosporins (cefazolin and cephalothin). propane acids (17:0 cyc and 19:0 cyc). The major cellular fatty acid peak was 16:0 (range, 22.8% -36.5%). Six hydroxy acids were detected (3OH-14:0, 2OH-16:1, 20H-16:0, 3OH-16:0, Discussion 2OH-18:1, and 2OH-19:0 cyc); 3-OH 10:0 was not detected. The MIDI Microbial Identification System identified the isoThis study represents the third report documenting B. gladioli as a human pathogen [6, 7] . In three of the four cases lates as B. gladioli by using the environmental library.
The results of testing these six strains by a variety of comreported herein, B. gladioli was isolated in pure cultures of specimens from sterile body sites. With the exception of patient 6 (present report), all other culty identifying these six strains. This system generated two high probability ( §85%) identifications of B. pickettii and four B. gladioli infections occurred in severely immunocompromised persons, including two with chronic granulomatous disease low probability (õ85%) identifications. Only one of the four low probability identifications gave B. gladioli as a choice.
[6], one with cystic fibrosis [7] , one with AIDS (present report), and one with liver failure (present report). Patients 1 -5 had Each of the other four systems generated fairly consistent misidentifications, although none of these results were identical.
multiple defects secondary to their primary disease, including chronic bacterial and fungal infections, multiple antimicrobial The antimicrobial susceptibility profiles for all six B. gladioli strains are listed in table 2. B. gladioli strains were susceptible regimens, immunosuppressive agents, transplantation, and/or drug abuse. Although the history of patient 6 is sketchy, it is to the quinolones, aminoglycosides, and imipenem. Most isolates were resistant to ampicillin; aztreonam; first-, second-, tempting to speculate that lymphadenitis may have resulted from an initial trauma, thus suggesting that B. gladioli (like and third-generation cephalosporins; and cephamycins. Suscep- many other nonfermentative organisms) primarily causes distions may have occurred as a consequence of impaired phagocytic function [6] as well as decreased complement-mediated ease in persons who are severely immunocompromised.
Since all six B. gladioli strains studied were highly susceptilysis. Regardless of the conditions predisposing persons to B. gladioli infections, the lack of any mortality directly attributble to lysis by 65% pooled human serum, the data suggest that most healthy individuals should be immune to infection under able to infection supports its low pathogenic potential. All six B. gladioli infections were described over a short normal conditions. Complement deficiencies have been detected in persons with liver disease [12] . In individuals with period (2 years). However, we do not believe that this organism is a new or emerging agent. Our earliest case (case 1) occurred cystic fibrosis, both hypocomplementemia [13] and the presence of serum factors that inhibit the lysis of gram-negative in 1983, and the report of Ross et al. [6] spurred us to describe our experiences with this bacterium. This agent probably causes bacteria have also been described [14] . Thus, B. gladioli infec- NOTE. AmB Å amphotericin B; Amp Å ampicillin; Atm Å aztreonam; CF Å cystic fibrosis; CGD Å chronic granulomatous disease; Cpfx Å ciprofloxacin; FUO Å fever of unknown origin; Gm Å gentamicin; Imi Å imipenem; Mtz Å metronidazole; PR Å present report; Sulb Å sulbactam; TMP-SMZ Å trimethoprimsulfamethoxazole; Vm Å vancomycin; ? Å unknown.
* Survived infection but died of acute lung rejection, cytomegalovirus pneumonia, and Aspergillus fumigatus lung infection.
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